<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36619561</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-2392</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in endocrinology</Title><ISOAbbreviation>Front Endocrinol (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Could VGF and/or its derived peptide act as biomarkers for the diagnosis of neurodegenerative diseases: A systematic review.</ArticleTitle><Pagination><StartPage>1032192</StartPage><MedlinePgn>1032192</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1032192</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fendo.2022.1032192</ELocationID><Abstract><AbstractText Label="BACKGROUND">The increasing ageing population has led to an increase in the prevalence of neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). However, as yet, there are no simple biomarkers to predict the onset of such diseases. Recently, VGF and its peptides have been highlighted in neurodegenerative diseases. VGF (non-acronymic) is a polypeptide induced in PC12 cells by neurotrophic factors.</AbstractText><AbstractText Label="OBJECTIVE">This systematic review aimed to determine whether VGF and/or its derived peptides can be used as biomarkers for the diagnosis of ALS, PD, and AD with specific attention to (1) the levels of VGF and/or its derived peptides, (2) amyloid-beta, (3) dopamine, and (4) cognitive score.</AbstractText><AbstractText Label="METHODOLOGY">A search was undertaken in the Ovid EMBASE, Cochrane Library, PubMed, Scopus, and Web of Science for observational studies. Publications that assessed the level of VGF and/or its derived peptides among people with neurodegenerative diseases and compared them with healthy people were included. The quality of the included studies was assessed using the National Heart, Lung, and Blood Institute Quality Assessment Tool.</AbstractText><AbstractText Label="RESULT">A search of the databases yielded 834 studies, of which, eight observational studies met the inclusion criteria with a total of 673 participants (51.7% males) aged &gt;18 years. Seven studies showed significant decreases in VGF and its derived peptides in adults with AD, PD, and ALS compared to healthy controls (<i>p</i>&lt;0.05). However, one study showed that there was no significant difference in VGF in AD compared to healthy control(<i>p</i>&gt;0.05). Furthermore, only one study reported that VGF levels were positively correlated with those of tissue dopamine but not with A&#x3b2;1-42, and low levels of VGF were associated to cognitive deficits.</AbstractText><AbstractText Label="CONCLUSION">The use of VGF and its derivatives for the diagnosis of PD, ALS, AD remains unclear, so further investigation of the role of VGF in neurodegenerative diseases and pathophysiology is needed to provide new insights.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Alqarni and Alsebai.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alqarni</LastName><ForeName>Saleha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Nutritional Sciences, School of Biosciences, University of Nottingham, Nottingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alsebai</LastName><ForeName>Mashael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Nutritional Sciences, School of Biosciences, University of Nottingham, Nottingham, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Endocrinol (Lausanne)</MedlineTA><NlmUniqueID>101555782</NlmUniqueID><ISSNLinking>1664-2392</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C510637">VGF protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009414" MajorTopicYN="N">Nerve Growth Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">VGF</Keyword><Keyword MajorTopicYN="N">VGF peptides</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">neurodegenerative diseases</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>9</Day><Hour>3</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36619561</ArticleId><ArticleId IdType="pmc">PMC9817138</ArticleId><ArticleId IdType="doi">10.3389/fendo.2022.1032192</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Deuschl G, Beghi E, Fazekas F, Varga T, Christoforidi KA, Sipido E, et al. . The burden of neurological diseases in Europe: An analysis for the global burden of disease study 2017. Lancet Public Health (2020) 5(10):e551&#x2013;67. doi: 10.1016/S2468-2667(20)30190-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(20)30190-0</ArticleId><ArticleId IdType="pubmed">33007212</ArticleId></ArticleIdList></Reference><Reference><Citation>Heemels MT. Neurodegenerative diseases. Nature (2016) 539(7628):179. doi: 10.1038/539179a</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/539179a</ArticleId><ArticleId IdType="pubmed">27830810</ArticleId></ArticleIdList></Reference><Reference><Citation>
National . How has life expectancy changed over time? - office for national statistics (2015). Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/articles/howhaslifeexpectancychangedovertime/2015-09-09.</Citation></Reference><Reference><Citation>
National . Life expectancy in Scotland 2017-2019 | national records of Scotland (2020). Available at: https://www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-theme/life-expectancy/life-expectancy-in-scotland/2017-2019.</Citation></Reference><Reference><Citation>
National . Overview of the UK population - office for national statistics (2017). Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/articles/overviewoftheukpopulation/july2017.</Citation></Reference><Reference><Citation>B&#xe9;jot Y, Yaffe K. Ageing population: A neurological challenge. Neuroepidemiology (2019) 52(1&#x2013;2):76&#x2013;7. doi: 10.1159/000495813</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000495813</ArticleId><ArticleId IdType="pubmed">30602150</ArticleId></ArticleIdList></Reference><Reference><Citation>Fineberg NA, Haddad PM, Carpenter L, Gannon B, Sharpe R, Young AH, et al. . The size, burden and cost of disorders of the brain in the UK. J Psychopharmacol Oxf Engl (2013) 27(9):761. doi: 10.1177/0269881113495118</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0269881113495118</ArticleId><ArticleId IdType="pmc">PMC3778981</ArticleId><ArticleId IdType="pubmed">23884863</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi A, Eldridge JD, Paterson BM. Molecular cloning of a gene sequence regulated by nerve growth factor. Science (1985) 229(4711):393&#x2013;5. doi: 10.1126/science.3839317</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.3839317</ArticleId><ArticleId IdType="pubmed">3839317</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho KO, Skarnes WC, Minsk B, Palmieri S, Jackson-Grusby L, Wagner JA. Nerve growth factor regulates gene expression by several distinct mechanisms. Mol Cell Biol (1989) 9(1):135. doi:&#xa0;10.1128/mcb.9.1.135</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mcb.9.1.135</ArticleId><ArticleId IdType="pmc">PMC362154</ArticleId><ArticleId IdType="pubmed">2538715</ArticleId></ArticleIdList></Reference><Reference><Citation>Salton SR, Fischberg DJ, Dong KW. Structure of the gene encoding VGF, a nervous system-specific MRNA that is rapidly and selectively induced by nerve growth factor in PC12 cells. Mol Cell Biol (1991) 11(5):2335. doi:&#xa0;10.1128/mcb.11.5.2335</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mcb.11.5.2335</ArticleId><ArticleId IdType="pmc">PMC359984</ArticleId><ArticleId IdType="pubmed">2017159</ArticleId></ArticleIdList></Reference><Reference><Citation>Alder J, Thakker-Varia S, Bangasser DA, Kuroiwa M, Plummer MR, Shors TJ, et al. . Brain-derived neurotrophic factor-induced gene expression reveals novel actions of VGF in hippocampal synaptic plasticity. J Neurosci (2003) 23(34):10800&#x2013;8. doi: 10.1523/JNEUROSCI.23-34-10800.2003</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.23-34-10800.2003</ArticleId><ArticleId IdType="pmc">PMC3374594</ArticleId><ArticleId IdType="pubmed">14645472</ArticleId></ArticleIdList></Reference><Reference><Citation>Jethwa PH, Warner A, Nilaweera KN, Brameld JM, Keyte JW, Carter WG, et al. . VGF-derived peptide, TLQP-21, regulates food intake and body weight in Siberian hamsters. Endocrinology (2007) 148(8):4044&#x2013;55. doi: 10.1210/en.2007-0038</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.2007-0038</ArticleId><ArticleId IdType="pubmed">17463057</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahm S, Mizuno TM, Wu TJ, Wisor JP, Priest CA, Kozak CA, et al. . Targeted deletion of the vgf gene indicates that the encoded secretory peptide precursor plays a novel role in the regulation of energy balance. Neuron (1999) 23(3):537&#x2013;48. doi: 10.1016/S0896-6273(00)80806-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80806-5</ArticleId><ArticleId IdType="pubmed">10433265</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahata SK, Mahata M, Fischer-Colbrie R, Winkler H. In Situ Hybridization: MRNA Levels of Secretogranin II, VGF and Peptidylglycine Alpha-Amidating Monooxygenase in Brain of Salt-Loaded Rats. Histochemistry (1993) 99(4):287&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">8500992</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis JE, Brameld JM, Jethwa PH. Neuroendocrine role for VGF. Front Endocrinol (2015) 6(FEB):3. doi: 10.3389/fendo.2015.00003</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2015.00003</ArticleId><ArticleId IdType="pmc">PMC4313783</ArticleId><ArticleId IdType="pubmed">25699015</ArticleId></ArticleIdList></Reference><Reference><Citation>Jethwa PH, Ebling FJP. Role of VGF-derived peptides in the control of food intake, body weight and reproduction. Neuroendocrinology (2008) 88(2):80&#x2013;7. doi: 10.1159/000127319</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000127319</ArticleId><ArticleId IdType="pubmed">18408361</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder SE, Cheng HW, Murray KD, Isackson PJ, McNeill TH, Salton SRJ. The messenger RNA encoding VGF, a neuronal peptide precursor, is rapidly regulated in the rat central nervous system by neuronal activity, seizure and lesion. Neuroscience (1997) 82(1):7&#x2013;19. doi: 10.1016/S0306-4522(97)00280-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-4522(97)00280-7</ArticleId><ArticleId IdType="pubmed">9483499</ArticleId></ArticleIdList></Reference><Reference><Citation>Cattaneo A, Sesta A, Calabrese F, Nielsen G, Riva MA, Gennarelli M. The expression of VGF is reduced in leukocytes of depressed patients and it is restored by effective antidepressant treatment. Neuropsychopharmacology (2010) 35(7):1423&#x2013;8. doi: 10.1038/npp.2010.11</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npp.2010.11</ArticleId><ArticleId IdType="pmc">PMC3055467</ArticleId><ArticleId IdType="pubmed">20164831</ArticleId></ArticleIdList></Reference><Reference><Citation>Canu N, Possenti R, Rinaldi AM, Trani E, Levi A. Molecular cloning and characterization of the human VGF promoter region. J Neurochemistry (1997) 68(4):1390&#x2013;9. doi: 10.1046/j.1471-4159.1997.68041390.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1997.68041390.x</ArticleId><ArticleId IdType="pubmed">9084409</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartolomucci A, La Corte G, Possenti R, Locatelli V, Rigamonti AE, Torsello A, et al. . TLQP-21, a VGF-derived peptide, increases energy expenditure and prevents the early phase of diet-induced obesity. Proc Natl Acad Sci United States America (2006) 103(39):14584&#x2013;9. doi: 10.1073/pnas.0606102103</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0606102103</ArticleId><ArticleId IdType="pmc">PMC1600003</ArticleId><ArticleId IdType="pubmed">16983076</ArticleId></ArticleIdList></Reference><Reference><Citation>Succu S, Mascia MS, Melis T, Sanna F, Melis MR, Possenti R, et al. . Pro-VGF-Derived peptides induce penile erection in Male rats: Involvement of paraventricular nitric oxide. Neuropharmacology (2005) 49(7):1017&#x2013;25. doi: 10.1016/j.neuropharm.2005.05.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2005.05.015</ArticleId><ArticleId IdType="pubmed">16087201</ArticleId></ArticleIdList></Reference><Reference><Citation>Trani E, Giorgi A, Canu N, Amadoro G, Rinaldi AM, Halban PA, et al. . Isolation and characterization of VGF peptides in rat brain. role of PC1/3 and PC2 in the maturation of VGF precursor. J Neurochemistry (2002) 81(3):565&#x2013;74. doi:&#xa0;10.1046/j.1471-4159.2002.00842.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2002.00842.x</ArticleId><ArticleId IdType="pubmed">12065665</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi A, Ferri GL, Watson E, Possenti R, Salton SRJ. Processing, distribution, and function of VGF, a neuronal and endocrine peptide precursor. Cell Mol Neurobiol (2004) 24(4):517&#x2013;33. doi: 10.1023/B:CEMN.0000023627.79947.22</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/B:CEMN.0000023627.79947.22</ArticleId><ArticleId IdType="pubmed">15233376</ArticleId></ArticleIdList></Reference><Reference><Citation>Toshinai K, Nakazato M. &#x2018;Neuroendocrine regulatory peptide-1 and -2: Novel bioactive peptides processed from VGF&#x2019;. Cell Mol Life Sciences&#x202f;: CMLS (2009) 66(11&#x2013;12):1939&#x2013;45. doi: 10.1007/s00018-009-8796-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-009-8796-0</ArticleId><ArticleId IdType="pubmed">19194657</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi H, Sasaki K, Satomi Y, Shimbara T, Kageyama H, Mondal MS, et al. . Peptidomic identification and biological validation of neuroendocrine regulatory peptide-1 and -2&#x2019;. J Biol Chem (2007) 282(36):26354&#x2013;60. doi: 10.1074/jbc.M701665200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M701665200</ArticleId><ArticleId IdType="pubmed">17609209</ArticleId></ArticleIdList></Reference><Reference><Citation>Toshinai K, Yamaguchi H, Kageyama H, Matsuo T, Koshinaka K, Sasaki K, et al. . &#x2018;Neuroendocrine regulatory peptide-2 regulates feeding behavior via the orexin system in the hypothalamus&#x2019;. Am J Physiol Endocrinol Metab (2010) 299:(3). doi: 10.1152/ajpendo.00768.2009</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.00768.2009</ArticleId><ArticleId IdType="pubmed">20551287</ArticleId></ArticleIdList></Reference><Reference><Citation>Brancia C, Noli B, Boido M, Boi A, Puddu R, Borghero G, et al. . VGF protein and its c-terminal derived peptides in amyotrophic lateral sclerosis: Human and animal model studies. PloS One (2016) 11(10):e0164689&#x2013;e0164689. doi: 10.1371/journal.pone.0164689</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0164689</ArticleId><ArticleId IdType="pmc">PMC5063282</ArticleId><ArticleId IdType="pubmed">27737014</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouillette J, Young D, During MJ, Quirion R. Hippocampal gene expression profiling reveals the possible involvement of Homer1 and GABAB receptors in scopolamine-induced amnesia. J Neurochemistry (2007) 102(6):1978&#x2013;89. doi: 10.1111/j.1471-4159.2007.04666.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.04666.x</ArticleId><ArticleId IdType="pubmed">17540011</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozdagi O, Rich E, Tronel S, Sadahiro M, Patterson K, Shapiro ML, et al. . The neurotrophin-inducible gene vgf regulates hippocampal function and behavior through a brain-derived neurotrophic factor-dependent mechanism. J Neurosci (2008) 28(39):9857&#x2013;69. doi: 10.1523/JNEUROSCI.3145-08.2008</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3145-08.2008</ArticleId><ArticleId IdType="pmc">PMC2820295</ArticleId><ArticleId IdType="pubmed">18815270</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakker-Varia S, Alder J. &#x2018;Neuropeptides in depression: Role of VGF&#x2019;. Behav Brain Res (2009) 197(2):262&#x2013;78. doi: 10.1016/j.bbr.2008.10.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2008.10.006</ArticleId><ArticleId IdType="pmc">PMC2648305</ArticleId><ArticleId IdType="pubmed">18983874</ArticleId></ArticleIdList></Reference><Reference><Citation>Cocco C, D&#x2019;Amato F, Noli B, Ledda A, Brancia C, Bongioanni P, et al. . Distribution of VGF peptides in the human cortex and their selective changes in parkinson&#x2019;s and alzheimer&#x2019;s diseases. J Anat (2010) 217(6):683&#x2013;93. doi: 10.1111/j.1469-7580.2010.01309.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-7580.2010.01309.x</ArticleId><ArticleId IdType="pmc">PMC3039181</ArticleId><ArticleId IdType="pubmed">21039478</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalb&#xf8;ge LS, Jacobsen JM, Mehrotra S, Mercer AJ, Cox N, Liu F, et al. . Evaluation of VGF peptides as potential anti-obesity candidates in pre-clinical animal models. Peptides (2021) 136:170444. doi:&#xa0;10.1016/j.peptides.2020.170444</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2020.170444</ArticleId><ArticleId IdType="pubmed">33245952</ArticleId></ArticleIdList></Reference><Reference><Citation>Severini C, Ciotti MT, Biondini L, Quaresima S, Rinaldi AM, Levi A, et al. . TLQP-21, a neuroendocrine VGF-derived peptide, prevents cerebellar granule cells death induced by serum and potassium deprivation. J Neurochemistry (2008) 104(2):534&#x2013;44. doi:&#xa0;10.1111/j.1471-4159.2007.05068.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.05068.x</ArticleId><ArticleId IdType="pubmed">18173805</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho K, Jang YJ, Lee SJ, Jeon YN, Shim YL, Lee JY, et al. . TLQP-21 mediated activation of microglial BV2 cells promotes clearance of extracellular fibril amyloid-&#x3b2;. Biochem Biophys Res Commun (2020) 524(3):764&#x2013;71. doi: 10.1016/j.bbrc.2020.01.111</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.01.111</ArticleId><ArticleId IdType="pubmed">32037089</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunsberger JG, Newton SS, Bennett AH, Duman CH, Russell DS, Salton SR, et al. . Antidepressant actions of the exercise-regulated gene VGF. Nat Med (2007) 13(12):1476&#x2013;82. doi: 10.1038/nm1669</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1669</ArticleId><ArticleId IdType="pubmed">18059283</ArticleId></ArticleIdList></Reference><Reference><Citation>Noda Y, Motoyama S, Nakamura S, Shimazawa M, Hara H. Neuropeptide VGF-derived peptide LQEQ-19 has neuroprotective effects in an In vitro model of amyotrophic lateral sclerosis. Neurochemical Res (2019) 44(4):897&#x2013;904. doi: 10.1007/s11064-019-02725-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-019-02725-4</ArticleId><ArticleId IdType="pubmed">30656593</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakker-Varia S, Behnke J, Doobin D, Dalal V, Thakkar K, Khadim F, et al. . &#x2018;VGF (TLQP-62)-Induced neurogenesis targets early phase neural progenitor cells in the adult hippocampus and requires glutamate and BDNF signaling&#x2019;. Stem Cell Res (2014) 12(3):762&#x2013;77. doi: 10.1016/j.scr.2014.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scr.2014.03.005</ArticleId><ArticleId IdType="pmc">PMC4991619</ArticleId><ArticleId IdType="pubmed">24747217</ArticleId></ArticleIdList></Reference><Reference><Citation>Riedl MS, Braun PD, Kitto KF, Roiko SA, Anderson LB, Honda CN, et al. . Proteomic analysis uncovers novel actions of the neurosecretory protein VGF in nociceptive processing. J Neurosci (2009) 29(42):13377&#x2013;88. doi: 10.1523/JNEUROSCI.1127-09.2009</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1127-09.2009</ArticleId><ArticleId IdType="pmc">PMC2801058</ArticleId><ArticleId IdType="pubmed">19846725</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;ltt&#xe4; M, Minthon L, Hansson O, Holm&#xe9;n-Larsson J, Pike I, Ward M, et al. . An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of alzheimer&#x2019;s disease. J Proteome Res (2015) 14(2):654&#x2013;63. doi: 10.1021/pr501076j</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr501076j</ArticleId><ArticleId IdType="pubmed">25490617</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmalm G, Sj&#xf6;din S, Simonsen AH, Hasselbalch SG, Zetterberg H, Brinkmalm A, et al. . A parallel reaction monitoring mass spectrometric method for analysis of potential CSF biomarkers for alzheimer&#x2019;s disease. Proteomics. Clin Appl (2018) 12(1). doi: 10.1002/prca.201700131</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prca.201700131</ArticleId><ArticleId IdType="pubmed">29028155</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, Burkhard P, et al. . A panel of cerebrospinal fluid potential biomarkers for the diagnosis of alzheimer&#x2019;s disease. Proteomics (2003) 3(8):1486&#x2013;94. doi: 10.1002/pmic.200300470</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmic.200300470</ArticleId><ArticleId IdType="pubmed">12923774</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinetti GM, Ungar LH, Lange DJ, Yemul S, Deng H, Yuan X, et al. . Identification of potential CSF biomarkers in ALS. Neurology (2006) 66(8):1218&#x2013;22. doi: 10.1212/01.wnl.0000203129.82104.07</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000203129.82104.07</ArticleId><ArticleId IdType="pubmed">16481598</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xfc;etschi U, Zetterberg H, Podust VN, Gottfries J, Li S, Hviid Simonsen A, et al. . Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp Neurol (2005) 196(2):273&#x2013;81. doi: 10.1016/j.expneurol.2005.08.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2005.08.002</ArticleId><ArticleId IdType="pubmed">16154129</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijte D, McDonnell LA, Balog CIA, Bossers K, Deelder AM, Swaab DF, et al. . &#x2018;A novel peptidomics approach to detect markers of alzheimer&#x2019;s disease in cerebrospinal fluid&#x2019;. Methods (San Diego Calif.) (2012) 56(4):500&#x2013;7. doi: 10.1016/j.ymeth.2012.03.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymeth.2012.03.018</ArticleId><ArticleId IdType="pubmed">22465281</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, Lange DJ, Ho L, Bonini S, Shao B, Salton SR, et al. . Vgf is a novel biomarker associated with muscle weakness in amyotrophic lateral sclerosis (ALS), with a potential role in disease pathogenesis. Int J Med Sci (2008) 5(2):92&#x2013;9. doi: 10.7150/ijms.5.92</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.5.92</ArticleId><ArticleId IdType="pmc">PMC2323610</ArticleId><ArticleId IdType="pubmed">18432310</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. . The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ (2021) 372. doi:&#xa0;10.1136/bmj.n71</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>
NIH . Study quality assessment tools (2014). Available at: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools.</Citation></Reference><Reference><Citation>Van Steenoven I, van der Flier WM, Scheltens P, Teunissen CE, Lemstra AW. &#x2018;VGF peptides in cerebrospinal fluid of patients with dementia with lewy bodies&#x2019;. Alzheimer&#x2019;s Res Ther (2019) 11:(1). doi: 10.1186/s13195-019-0537-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-019-0537-5</ArticleId><ArticleId IdType="pmc">PMC6788069</ArticleId><ArticleId IdType="pubmed">31601267</ArticleId></ArticleIdList></Reference><Reference><Citation>Llano DA, Devanarayan P, Devanarayan V. VGF in cerebrospinal fluid combined with conventional biomarkers enhances prediction of conversion from MCI to AD. Alzheimer Dis Associated Disord (2019) 33(4):307&#x2013;14. doi: 10.1097/WAD.0000000000000328</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0000000000000328</ArticleId><ArticleId IdType="pubmed">31305322</ArticleId></ArticleIdList></Reference><Reference><Citation>Cocco C, Corda G, Lisci C, Noli B, Carta M, Brancia C, et al. . VGF peptides as novel biomarkers in parkinson&#x2019;s disease. Cell Tissue Res (2020) 379(1):93&#x2013;107. doi: 10.1007/s00441-019-03128-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00441-019-03128-1</ArticleId><ArticleId IdType="pubmed">31713727</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T. Ageing, neurodegeneration and brain rejuvenation. Nature (2016) 539(7628):180&#x2013;6. doi: 10.1038/nature20411</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20411</ArticleId><ArticleId IdType="pmc">PMC5172605</ArticleId><ArticleId IdType="pubmed">27830812</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia E, Rios C, Sotelo J. Ventricular injection of nerve growth factor increases dopamine content in the striata of MPTP-treated mice. Neurochemical Res (1992) 17(10):979&#x2013;82. doi: 10.1007/BF00966824</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00966824</ArticleId><ArticleId IdType="pubmed">1508308</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri GL, Noli B, Brancia C, D&#x2019;Amato F, Cocco C. VGF: An inducible gene product, precursor of a diverse array of neuro-endocrine peptides and tissue-specific disease biomarkers. J Chem Neuroanat (2011) 42(4):249&#x2013;61. doi: 10.1016/j.jchemneu.2011.05.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchemneu.2011.05.007</ArticleId><ArticleId IdType="pubmed">21621608</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokizane K, Konishi H, Yasui M, Ogawa T, Sasaki K, Minamino N, et al. . &#x2018;Continuous stress promotes expression of VGF in melanotroph via suppression of dopamine&#x2019;. Mol Cell Endocrinol (2013) 372(1&#x2013;2):49&#x2013;56. doi: 10.1016/j.mce.2013.03.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mce.2013.03.012</ArticleId><ArticleId IdType="pubmed">23541636</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawley R, Scheibe R, Wagner J. NGF induces the expression of the VGF gene through a CAMP response element. J Neurosci (1992) 12(7):2573&#x2013;81. doi: 10.1523/JNEUROSCI.12-07-02573.1992</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.12-07-02573.1992</ArticleId><ArticleId IdType="pmc">PMC6575845</ArticleId><ArticleId IdType="pubmed">1377233</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckmann ND, Lin WJ, Wang M, Cohain AT, Charney AW, Wang P, et al. . Multiscale causal networks identify VGF as a key regulator of alzheimer&#x2019;s disease. Nat Commun (2020) 11(1):18. doi:&#xa0;10.1038/s41467-020-17405-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17405-z</ArticleId><ArticleId IdType="pmc">PMC7414858</ArticleId><ArticleId IdType="pubmed">32770063</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin W-J, Jiang C, Sadahiro M, Bozdagi O, Vulchanova L, Alberini CM, et al. . VGF and its c-terminal peptide TLQP-62 regulate memory formation in hippocampus via a BDNF-TrkB-Dependent mechanism. J Neurosci (2015) 35(28):10343&#x2013;56. doi: 10.1523/JNEUROSCI.0584-15.2015</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0584-15.2015</ArticleId><ArticleId IdType="pmc">PMC4502270</ArticleId><ArticleId IdType="pubmed">26180209</ArticleId></ArticleIdList></Reference><Reference><Citation>Cero C, Vostrikov VV, Verardi R, Severini C, Gopinath T, Braun PD, et al. . The TLQP-21 peptide activates the G-Protein-Coupled receptor C3aR1 via a folding-upon-Binding mechanism. Structure (2014) 22(12):1744&#x2013;53. doi: 10.1016/j.str.2014.10.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2014.10.001</ArticleId><ArticleId IdType="pmc">PMC4353613</ArticleId><ArticleId IdType="pubmed">25456411</ArticleId></ArticleIdList></Reference><Reference><Citation>El Gaamouch F, Audrain M, Lin WJ, Beckmann N, Jiang C, Hariharan S, et al. . VGF-derived peptide TLQP-21 modulates microglial function through C3aR1 signaling pathways and reduces neuropathology in 5xFAD mice. Mol Neurodegeneration (2020) 15(1):1&#x2013;19. doi: 10.1186/s13024-020-0357-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-0357-x</ArticleId><ArticleId IdType="pmc">PMC6954537</ArticleId><ArticleId IdType="pubmed">31924226</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang EJ, Reichardt LF. Neurotrophins: Roles in neuronal development and function. Annu Rev Neurosci (2001) 24:677&#x2013;736. doi: 10.1146/annurev.neuro.24.1.677</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.24.1.677</ArticleId><ArticleId IdType="pmc">PMC2758233</ArticleId><ArticleId IdType="pubmed">11520916</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha C, Brambilla R, Thomas KL. A simple role for BDNF in learning and memory? Front Mol Neurosci (2010) 3(February):1&#x2013;14. doi: 10.3389/neuro.02.001.2010</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/neuro.02.001.2010</ArticleId><ArticleId IdType="pmc">PMC2821174</ArticleId><ArticleId IdType="pubmed">20162032</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW. BDNF MRNA is decreased in the hippocampus of individuals with alzheimer&#x2019;s disease. (1991) 7. doi: 10.1016/0896-6273(91)90273-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(91)90273-3</ArticleId><ArticleId IdType="pubmed">1742020</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Fukumoto H, Orne J, Klucken J, Raju S, Vanderburg CR, et al. . Decreased levels of BDNF protein in Alzheimer temporal cortex are independent of BDNF polymorphisms. Exp Neurol (2005) 194(1):91&#x2013;6. doi: 10.1016/j.expneurol.2005.01.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2005.01.026</ArticleId><ArticleId IdType="pubmed">15899246</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng S, Wuu J, Mufson EJ, Fahnestock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of alzheimer&#x2019;s disease. J Neurochemistry (2005) 93(6):1412&#x2013;21. doi: 10.1111/j.1471-4159.2005.03135.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03135.x</ArticleId><ArticleId IdType="pubmed">15935057</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol (2009) 5(6):311&#x2013;22. doi: 10.1038/nrneurol.2009.54</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2009.54</ArticleId><ArticleId IdType="pubmed">19498435</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito W, Chehab M, Thakur S, Li J, Morozov A. BDNF-restricted knockout mice as an animal model for aggression. Genes Brain Behav (2011) 10(3):365&#x2013;74. doi: 10.1111/j.1601-183X.2010.00676.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1601-183X.2010.00676.x</ArticleId><ArticleId IdType="pmc">PMC3080454</ArticleId><ArticleId IdType="pubmed">21255268</ArticleId></ArticleIdList></Reference><Reference><Citation>Afzal S, Bojesen SE, Nordestgaard BG. Reduced 25-hydroxyvitamin d and risk of alzheimer&#x2019;s disease and vascular dementia. Alzheimer&#x2019;s Dementia (2014) 10(3):296&#x2013;302. doi: 10.1016/j.jalz.2013.05.1765</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2013.05.1765</ArticleId><ArticleId IdType="pubmed">23871764</ArticleId></ArticleIdList></Reference><Reference><Citation>Littlejohns TJ, Henley WE, Lang IA, Annweiler C, Beauchet O, Chaves PHM, et al. . Vitamin d and the risk of dementia and Alzheimer disease. Neurology (2014) 83(10):920&#x2013;8. doi: 10.1212/WNL.0000000000000755</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000755</ArticleId><ArticleId IdType="pmc">PMC4153851</ArticleId><ArticleId IdType="pubmed">25098535</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson AL, Mancini M, Horak FB. The relationship between balance control and vitamin d in parkinson&#x2019;s disease-a pilot study. Movement Disord (2013) 28(8):1133&#x2013;7. doi: 10.1002/mds.25405</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.25405</ArticleId><ArticleId IdType="pmc">PMC3812066</ArticleId><ArticleId IdType="pubmed">23554003</ArticleId></ArticleIdList></Reference><Reference><Citation>Latimer CS, Brewer LD, Searcy JL, Chen K-C, Popovi&#x107; J, Kraner SD, et al. . Vitamin d prevents cognitive decline and enhances hippocampal synaptic function in aging rats. Proc Natl Acad Sci (2014) 111(41):E4359&#x2013;66. doi: 10.1073/pnas.1404477111</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1404477111</ArticleId><ArticleId IdType="pmc">PMC4205629</ArticleId><ArticleId IdType="pubmed">25267625</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis JE, Brameld JM, Hill P, Wilson D, Barrett P, Ebling FJP, et al. . Thyroid hormone and vitamin d regulate VGF expression and promoter activity. J Mol Endocrinol (2016) 56(2):123&#x2013;34. doi: 10.1530/JME-15-0224</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/JME-15-0224</ArticleId><ArticleId IdType="pmc">PMC4705542</ArticleId><ArticleId IdType="pubmed">26643910</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewer LD, Thibault V, Chen KC, Langub MC, Landfield PW, Porter NM. Vitamin d hormone confers neuroprotection in parallel with downregulation of l-type calcium channel expression in hippocampal neurons. J Neurosci (2001) 21(1):98&#x2013;108. doi: 10.1523/JNEUROSCI.21-01-00098.2001</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.21-01-00098.2001</ArticleId><ArticleId IdType="pmc">PMC6762438</ArticleId><ArticleId IdType="pubmed">11150325</ArticleId></ArticleIdList></Reference><Reference><Citation>Oermann E, Bidmon HJ, Witte OW, Zilles K. Effects of 1&#x3b1;,25 dihydroxyvitamin d 3 on the expression of HO-1 and GFAP in glial cells of the photothrombotically lesioned cerebral cortex. J Chem Neuroanat (2004) 28(4):225&#x2013;38. doi: 10.1016/j.jchemneu.2004.07.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchemneu.2004.07.003</ArticleId><ArticleId IdType="pubmed">15531134</ArticleId></ArticleIdList></Reference><Reference><Citation>Celli A, Treves C, Stio M. Vitamin d receptor in SH-SY5Y human neuroblastoma cells and effect of 1,25-dihydroxyvitamin D3 on cellular proliferation. Neurochemistry Int (1999) 34(2):117&#x2013;24. doi: 10.1016/S0197-0186(98)00075-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-0186(98)00075-8</ArticleId><ArticleId IdType="pubmed">10213069</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>